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http://dx.doi.org/10.1016/j.ccell.2015.02.003SUMMARYStudying 830 pre-B ALL cases from four clinical trials, we found that human ALL can be divided into two
fundamentally distinct subtypes based on pre-BCR function. While absent in the majority of ALL cases, tonic
pre-BCR signaling was found in 112 cases (13.5%). In these cases, tonic pre-BCR signaling induced activa-
tion of BCL6, which in turn increased pre-BCR signaling output at the transcriptional level. Interestingly,
inhibition of pre-BCR-related tyrosine kinases reduced constitutive BCL6 expression and selectively killed
patient-derived pre-BCR+ ALL cells. These findings identify a genetically and phenotypically distinct subset
of human ALL that critically depends on tonic pre-BCR signaling. In vivo treatment studies suggested that
pre-BCR tyrosine kinase inhibitors are useful for the treatment of patients with pre-BCR+ ALL.Significance
Recent work successfully introduced BCR signaling inhibitors
phoma, for example, Ibrutinib (BTK) and Idelalisib (PI3Kd), for
knownwhether pre-BCR signaling represents a therapeutic tar
of human ALL cases that critically depends on tonic pre-BCR s
itors of SYK and SRC tyrosine kinases downstream of the preinto patient care for various subtypes of mature B cell lym-
germinal center-derived B cell lymphoma. However, it is not
get in pre-B ALL. Here we report the identification of a subset
ignaling and is selectively sensitive to small molecule inhib-
-BCR.
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Figure 1. Expression and Activity of the Pre-BCR Receptor in Subsets of Pre-B ALL
(A) Flow cytometry staining for cell cytoplasmic mHC.
(B) Cell surface expression of the surrogate light-chain components l5 (IGLL1) and VpreB.
(C) Ca2+ mobilization in response to pre-BCR engagement using mHC-specific antibodies in different subtypes of ALL cases.
(legend continued on next page)
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INTRODUCTION
Bone marrow progenitor cells in mice produce approximately 10
million pre-B cells daily (Osmond, 1991), the vast majority of
which is eliminated at the pre-B cell receptor (BCR) checkpoint
(Sakaguchi and Melchers, 1986). Early pre-B cells are pro-
grammed to die unless they productively rearrange VHDJH
gene segments and are rescued by ‘‘tonic’’ pre-BCR signal ac-
tivity into the long-lived pool of mature peripheral B cells (Rajew-
sky, 1996). Even in mature B cells, continuous tonic signaling
from the BCR is required for B cell survival and maintenance
and conditional ablation of tonic BCR signaling results in rapid
B cell depletion (Kraus et al., 2004). Interestingly, however, loss
of tonic BCR signaling can be rescued by activation of PI3K-
AKT signaling (Srinivasan et al., 2009), identifying PI3K-AKT as
a central survival pathway downstream of the (pre-BCR) BCR.
Tonic pre-BCR signaling involves constitutive activity of the
proximal pre-BCR-associated SRC family kinases LYN, FYN,
and BLK (Saijo et al., 2003), as well as SYK and ZAP70
(Schweighoffer et al., 2003), which then activate PI3K (Guo
et al., 2000; Okada et al., 2000). Recent work highlighted the
particular importance of the PI3K p110d (PIK3CD) isoform for
pre-BCR survival signaling during early B cell development
(Ramadani et al., 2010). The discovery that most subtypes of B
cell lymphoma critically depend on BCR signaling (Davis et al.,
2010; Schmitz et al., 2012) has led to the development of new
targeting strategies that focus on BCR signaling at the level of
SRC kinases (Lyn, Fyn, and Blk), SYK/ZAP70 and PI3Kd (Burger
and Okkenhaug, 2014; Chen et al., 2006, 2013; Cheng et al.,
2011; Ke et al., 2009; Yang et al., 2008). In addition, small mole-
cule inhibition of BTK, which mediates ‘‘chronic active BCR
signaling’’ in activated B cell-like (ABC) diffuse large B cell
lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), and
mantle cell lymphoma (MCL) has achievedmajor clinical success
in the treatment of these diseases (Byrd et al., 2013a; Davis et al.,
2010; Schmitz et al., 2012; Wang et al., 2013). While the role of
BCR signaling in the biology and treatment has been elucidated
in all major B cell lymphoma subtypes, the role of pre-BCR
signaling has not been systematically studied in human pre-B
acute lymphoblastic leukemia (ALL).
Goals of the present study were (1) to identify cases of human
pre-B ALL with tonic or chronic active pre-BCR signaling, (2) to
estimate their frequency, (3) to determine the role of pre-BCR
signaling in specific pre-B ALL subtypes, (4) to identify cooperat-
ing genetic lesions, and (5) to develop a concept for therapeutic
targeting of the pre-BCR pathway in human pre-B ALL.
RESULTS
Expression and Activity of the Pre-BCR Defines a
Distinct Subtype of Human ALL
To elucidate pre-BCR expression and function in pre-B ALL
cells, we measured expression of the immunoglobulin m heavy(D) Patient-derived Pre-BCR+ ALL cells were treated with or without Dasatinib
measured by western blot.
(E) Protein expression and phosphorylation levels of LYN, SRC, PIK3R1 (p85), PIK
ALL patient samples (MDACC 1983–2007, n = 208). y axis shows log2 expression
See also Figure S1 and Tables S1–S3.chain (mHC) and the pre-BCR surrogate light-chain components
l5 (IGLL1) and VpreB on a series of 31 patient-derived pre-B ALL
xenograft samples and 15 ALL cell lines by flow cytometry
(Tables S1–S3). Twenty eight of the 46 pre-B ALL samples and
cell lines tested lacked surface pre-BCR expression, including
5 MLL-rearranged (MLLr), 16 BCR-ABL1, 2 ETV6-RUNX1, and
5 ALL with other abnormalities. Of the 18 pre-BCR+ ALL cases,
14 harbored a PBX1 gene rearrangement (1q23), 1 carried a
deletion at 6q21, 1 carried both PBX1 gene rearrangement and
6q21 deletion, and 2 harbored PDGFRB gene rearrangements
(Figures 1A, 1B, and S1A–S1I). Engagement of the pre-BCR us-
ing mHC-specific antibodies resulted in strong Ca2+ mobilization
from cytoplasmic stores in all 7 pre-BCR+ ALL cases tested but
not in any of the 19 other cases (Figures 1C and S1A–S1I). These
findings suggest that most cases of human ALL lack pre-BCR
signaling (pre-BCR), whereas a distinct ALL subgroup (pre-
BCR+) exists that is defined by pre-BCR expression and activity.
Indeed, key components of the pre-BCR signaling, including
SRC family kinases (LYN, BLK), SYK, BTK, and PLCg2 were
constitutively active in six pre-BCR+ ALL samples (Figure 1D).
Interestingly, phosphorylation of these molecules was sensitive
to treatment of the dual ABL1/SRC-BTK inhibitor Dasatinib
(Figure 1D).
Tonic Pre-BCR Signaling, Including Activation of SRC,
SYK, and PI3K, in a Subset of Human ALL
To compare baseline signaling activity of pre-BCR and pre-
BCR+ ALL cells in a large cohort of patients (MDACC 1983–
2007, n = 208), we divided patient samples into two groups
based on flow cytometry measurements of pre-BCR (mHC)
expression and the Iga signaling chain CD79A (Figure S1J).
None of the pre-BCR+ ALL cases in this cohort (n = 26) ex-
pressed the stem/progenitor cell antigen CD34 and CD25, which
are both expressed on the surface of most of the 182 pre-BCR
ALL cases (Figure S1K). Using a panel of 133 validated anti-
bodies, we interrogated those 208 pre-B ALL samples at the
time of diagnosis for expression and activity of 66 signaling mol-
ecules on reverse phase protein arrays (RPPAs) (Tibes et al.,
2006). RPPA analyses revealed that pre-BCR+ ALL cells exhibit
significantly higher expression and activity of SRC family ki-
nases, including LYN, and strong constitutive activity of multiple
components of the PI3K-AKT pathway, including PIK3R1 (p85a),
PIK3CD (p110d), AKT1-pS473/T308, MTOR-pS2448, RPS6KB-
pS371, and RPS6-pS235/S236 (Figures 1E and S1L). Consistent
with strong PI3K-AKT signaling, expression and activity of
PTEN, a negative regulator of PI3K-AKT signaling, are low in
pre-BCR+ ALL cells. These findings are consistent with the es-
tablished central role of SRC/LYN kinase (Saijo et al., 2003)
and PI3K-AKT signaling (Srinivasan et al., 2009), in particular
PIK3d (Ramadani et al., 2010), in tonic pre-BCR signaling. Pre-
BCR+ ALL cases are also distinct from pre-BCR ALL cases
by particularly low levels of STAT5 expression and activity (Fig-
ure S1L). We conclude that pre-BCR+ ALL cells are defined by(25 mmol/l, 24 hr). Phosphorylation of SRC, BLK, SYK, BTK, and PLCg2 was
3CD (p110d), and AKT were measure by RPPAs in pre-BCR+ versus pre-BCR
values of RPPA data; p values were calculated from two-sided Wilcoxon test.
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a distinct signaling phenotype, including constitutive SRC and
PI3K-AKT signaling and lack of STAT5 activity.
Tonic Pre-BCR Signaling Is Associated with a Distinct
Gene Expression Profile in Human ALL
Upregulation of tonic pre-BCR signaling at the expense of STAT5
in pre-B ALL is reminiscent of negative regulation of IL7R/STAT5
upon pre-BCR activation during normal early B cell development
(Ochiai et al., 2012). The shift from IL7R/STAT5 to pre-BCR
signaling during early B cell differentiation triggers profound
gene expression changes. Therefore, we analyzed the gene
expression data from three pre-B ALL clinical trials for children
(COGP9906, n = 207; Harvey et al., 2010; and St. Jude Research
Hospital, n = 132; Ross et al., 2003) and adults (ECOGE2993, n =
191; Geng et al., 2012). Patients in these trials were classified as
pre-BCR or pre-BCR+ based on pre-BCR expression (IGLL1,
IGLL3, VPREB1, VPREB3, IGHM) and its associated signaling
molecules SYK and ZAP70 (Figures 2A–2C). To identify a com-
mon gene expression signature for pre-BCR+ ALL, we performed
a supervisedanalysis of themicroarraydata and identifieda set of
40 genes concordantly differentially expressed in pre-BCR+
versus pre-BCR ALL in all three clinical cohorts (Figures 2A–
2C). Theupregulatedgenes includepre-BCRsignalingmolecules
(PRKCZ,BLNK,BLK, LYN,MERTK,ROR1) and transcription fac-
tors that promote B cell differentiation (BCL6, BACH2, IRF4,
TCF3, POU2AF1). Downregulated genes include IL2RA (CD25)
and CD34, confirming flow cytometry data from the MDACC
cohort (Figure S1K), the STAT5 target genes (ID2, CD69, CD99,
ITGA6, CCND2, SOCS2) and PRDM1 (BLIMP1) (Figures 2A–2C).
Frequent Rearrangement of PBX1 in pre-BCR+ ALL
We studied the coding capacity of immunoglobulin heavy-chain
VHDJH gene rearrangements in 152 primary pre-B ALL samples
and normal B cell precursors as reference (Trageser et al., 2009).
Human bone marrow pro-B, pre-B, and immature B cells from
healthy donors (n = 2) were studied by single-cell PCR. Inmarked
contrast to other pre-B ALL subsets, most cases with TCF3-
PBX1 rearrangement and/or 6q21 deletion carried productively
rearranged IGHM alleles and showed evidence of selection for
expression of in-frame VHDJH gene rearrangements, like normal
pre-B cells (Figures 2D and 2E; Table S4). In contrast, productive
VHDJH gene rearrangements were negatively selected in all other
ALL subsets. Combining data from four clinical trials (n = 830;
Table S5), we collectively found evidence of pre-BCR function
in 112 cases (13.5%). In agreement with a recent study by others
and us (Bicocca et al., 2012), pre-BCR expression was frequent
among ALL cases with PBX1 rearrangement or duplication and
6q21 deletion, but rare or absent in cases with MLLr, BCR-
ABL1, ETV6-RUNX1, and hyperdiploid ALL (Figure 2F; Tables
S5 and S6).
TCF3-PBX1 Binds to and Upregulates Pre-BCR Genes in
Human ALL Cells
PBX1 is a proto-oncogene with a critical role in hematopoiesis
and lymphopoiesis (Sanyal et al., 2007). In pre-B ALL, PBX1
(1q23) is frequently rearranged to the B cell-specific TCF3
(19p13) locus, encoding E2A (E12 and E47) transcription factors.
In these cases, the N-terminal transcriptional activation domains
of TCF3 (exons 1-16, TCF3N) are fused to the C-terminal Hox412 Cancer Cell 27, 409–425, March 9, 2015 ª2015 Elsevier Inc.cooperative motif and homeodomain of PBX1 (exons 4-9,
PBX1C) (Nourse et al., 1990). To identify targets of oncogenic
TCF3-PBX1 activity, we performed chromatin immunoprecipita-
tion (ChIP), followed by massively parallel DNA sequencing
(ChIPseq), using antibodies against the PBX1C, the TCF3N,
and the TCF3-PBX1 co-activator p300 (Bayly et al., 2004) in
a TCF3-PBX1 ALL cell line (697) and a primary TCF3-PBX1
ALL sample (ICN12) (Figure S2A). ChIPseq data revealed that
TCF3-PBX1, in concert with its coactivator p300, strongly bound
to promoter regions of genes that encode key components of
the pre-BCR, including IGLL1, VPREB1, VPREB3, CD79A, and
CD79B, as well as mHC enhancer regions (Figure 3A). Specific
binding of TCF3-PBX1 to these six loci was confirmed by sin-
gle-locus quantitative ChIP (qChIP), using the fusion-specific
TCF3-PBX1-hf (Figures 3B and S2B) and the TCF3N, PBX1C,
and p300 antibodies (Figures S2C–S2F). To identify genome-
wide target genes that are directly regulated by TCF3-PBX1,
we matched TCF3-PBX1 binding (ChIPseq; Figure S2D–S2F)
with specific gene expression changes that distinguish TCF3-
PBX1 cases from other pre-B ALL subsets (Ross et al., 2003).
Among the 1,343 TCF3-PBX1 (PBX1C, TCF3N and p300) target
genes in promoter regions (within 2-kb distance from tran-
scription start site), 99 were specifically upregulated, including
multiple pre-BCR components (IGLL1, VREB1, VREB3, IGHM)
and pre-BCR downstream signaling molecules (BLK, LCK,
SYK, ZAP70, PIK3CD, PIK3R1). In addition, 111 targets were
significantly downregulated in TCF3-PBX1 compared to other
pre-B ALL subtypes, including the STAT5 target genes CD69
and SOCS2 (Figures 3C and 3D). A pathway analysis of TCF3-
PBX1 ChIPseq/gene expression targets suggested that TCF3-
PBX1 is a positive regulator of B cell development and BCR
signaling and negatively regulated STAT5 (Figure 3E).
To further test whether gene rearrangement and oncogenic
activation of TCF3-PBX1 induces pre-BCR activity, we studied
full-blown ALL populations that had developed after latencies
of 90–180 days in the bone marrow from the TCF3-PBX1-,
BCR-ABL1-, and MLL-AF4-transgenic mice. Flow cytometry of
surface mHC and CD79B (Igb) expression confirmed that ALL
cells developing in TCF3-PBX1-transgenic mice are character-
ized by pre-BCR expression in contrast to pre-BCR ALL in
BCR-ABL1- and MLL-AF4-transgenic mice (Figure 3F).
Pre-BCR Signaling Regulates the Balance between
BCL6 and STAT5 Activity in Human ALL
Studying gene expression changes in 516 ALL cases from three
clinical trials (St Jude, COG P9906, ECOG E2993; Table S5),
we found that pre-BCR+ ALL cells (n = 71, 13.8%) exhibit consis-
tently higher expression levels of BCL6 than pre-BCR cases
(n = 445, 86.2%; Figures 2A–2C). Quantitative RT-PCR analyses
confirmed 6- to 30-fold higher mRNA and protein levels of BCL6
in TCF3-PBX1ALL comparedwith other ALL subsets (Figures 4A
and S3A). These findings suggested that BCL6 may be a direct
target of TCF3-PBX1 and other oncogenic transcription factors
that drive pre-BCR+ ALL. However, ChIPseq and qChIP analysis
showed no evidence of binding of TCF3-PBX1 to the BCL6 locus
(Figures S3B and S3C), indicating that TCF3-PBX1 induces
BCL6 expression through an indirect mechanism.
Recent studies by us and others (Duy et al., 2010; Swamina-
than et al., 2013) revealed a critical role of BCL6 as a survival
A B C
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Figure 2. Pre-BCR Signaling in ALL Is Associated with a Distinct Gene Expression and Signal Transduction Phenotype
(A–C) Gene expressionmicroarray data was analyzed from three cohorts of pre-B ALL patient samples for children (St. Jude Research Hospital; COGP9906) and
adults (ECOG E2993). In each dataset, the patient samples were ranked based on their average mRNA expression levels of pre-BCR molecules (IGLL1, IGLL3,
VPREB1, VPREB3, IGHM, SYK, and ZAP70). The top 15% and the bottom 25% cases were considered as the pre-BCR+ and pre-BCR and subject to the
clustering analysis. Supervised analysis on pre-BCR+ versus pre-BCR ALL revealed a 40-gene expression signature that is significantly upregulated or
downregulated across all three cohorts. The color scale bar represents the relative log2 expression changes.
(D) The configuration of the mHC locus (IGHM) was studied in human bone marrow pro-B, pre-B, and immature B cells.
(E) Different subtypes of ALL patient samples (n = 152). The y axis shows frequencies of normal B cells or ALL clones with a functional or a non-functional IGHM
gene rearrangement in these populations.
(F) Frequency of different cytogenetic subtypes of pre-B ALL cases as pre-BCR+ or pre-BCR based on four clinical trials (n = 830, MDACC, St. Jude, COG
and ECOG).
See also Tables S4–S6.
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Figure 3. TCF3-PBX1 Fusion Protein Binds to and Upregulates Genes Encoding Pre-BCR Components
(A) ChIPseq tracks for TCF3N, PBX1C, and p300 antibodies versus input in a TCF3-PBX1 ALL line 697 and a primary sample ICN12 on IGLL1, VPREB1, VPREB3,
CD79A, and CD79B promoter regions and the IGHM enhancer regions (Em). Gene models were shown in UCSC genome browser hg18.
(B) QChIP validation using an HA antibody that is specific for the HA-Flag-tagged TCF3-PBX1 fusion or an EV as control. NCAPD2 serves as a negative control
gene. Data represent means ± SEM (n = 3); p values are from t test.
(C) The scatter plot shows the average gene expression values of the TCF3-PBX1-rearranged (x axis) versus the non-TCF3-PBX1-rearranged ALL patient
samples (y axis) from the St. Jude dataset on the TCF3-PBX1 target genes (n = 1,343). Blue and red highlighted are the downregulated (n = 111) and upregulated
(n = 99) genes (>1.5-fold change).
(D) The heat-map representation for some upregulated or downregulated genes. The color scale bar represents the log2 expression changes.
(legend continued on next page)
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factor at the pre-BCR checkpoint during normal B cell develop-
ment. In BCR-ABL1 ALL (pre-BCR), inhibition of STAT5 activity
by treatment with tyrosine kinase inhibitors induced strong
expression of BCL6 (Duy et al., 2011). Likewise, in our western
blot analysis, while pre-BCR+ (TCF3-PBX1) ALL cases ex-
pressed high levels of BCL6 in the absence of STAT5 activity,
we observed the converse in pre-BCR (BCR-ABL1) ALL cells
(Figure 4A). To test whether pre-BCR signaling directly affects
the balance between BCL6 and STAT5, we used an inducible
system for pre-BCR activation in mouse ALL cells. To this end,
Rag2/ mouse ALL cells, lacking the ability of endogenous
pre-BCR expression, were engineered to express a prerear-
ranged tetracyclin-inducible mHC, which results in subsequent
pre-BCR expression (Trageser et al., 2009). Inducible pre-BCR
activation resulted in a massive increase of BCL6 protein levels
(40-fold) and concomitant silencing of STAT5 activity (p-Y694;
Figure 4B). Similarly, complementation of a defective pre-BCR
signaling chain in Blnk/ or Ighm/mouse ALL cells by recon-
stitution of Blnk or mHC-expression caused dramatic upregula-
tion of BCL6 at the expense of STAT5 activity (p-Y694; Figure 4B).
Likewise, Cre-mediated deletion of Stat5 in Stat5a/bfl/fl ALL cells
was sufficient to increase BCL6 protein levels (Figure 4C). These
experiments provide genetic evidence that the balance between
BCL6 and STAT5-activity is directly influenced by pre-BCR
signaling and hence suggests that high expression levels of
BCL6 represent as a surrogate marker for pre-BCR activity in
human ALL cells.
BCL6 Expression Represents a Surrogate Marker for
Pre-BCR Activity in Human ALL
Immunohistochemical analyses for expression of the pre-BCR
(mHC) and BCL6 were performed on bone marrow biopsies
from 72 ALL patients. These analyses confirmed that all 12
pre-BCR+ (mHC+) ALL cases express BCL6 at high levels (Fig-
ure S3D; Table S7). These cases carried lesions affecting
PBX1, through TCF3-PBX1 and/or gain of 1q23 encompassing
PBX1. In contrast, 60 other cases lacked both BCL6 and mHC
surface expression (Figure S3E). We next performed double-
stainings for BCL6 and mHC on the same slides, confirming
that pre-BCR ALL cells express neither mHC nor BCL6. In
pre-BCR+ ALL cases, virtually all cells expressed both surface
mHC and BCL6 at levels comparable to mature B cell lymphoma
carrying IGH-BCL6 rearrangement (Figure 4D). Bone marrow
biopsies from pre-BCR+ ALL cases included various degrees
of admixtures of normal bone marrow cells that lacked both
mHC and BCL6 expression.
SYK Tyrosine Kinase Signaling Is Required for BCL6
Activation Downstream of Tonic Pre-BCR Signaling
Based on the finding that BCL6 is induced by pre-BCR signaling
and is a potential target for drug treatment in pre-BCR+ ALL cells,
we measured the effects of small molecule inhibitors of proximal
pre-BCR tyrosine kinases on BCL6 expression. While 57 of 61(E) Ingenuity pathway analysis for the upregulated and downregulated genes. Th
(F) Flow cytometry staining for cytoplasmic mHC, surface CD79B, and CD19 in mo
TCF3-PBX1, or EV vector or full-blown ALL populations that had developed after la
TCF3-PBX1-transgenic mice.
See also Figure S2.ALL cases with PBX1-rearrangement or duplication showed
evidence of tonic pre-BCR signaling (Figure 2F; Table S5), we
did not find pre-BCR activity in any of 196 cases with Ph+ ALL
(BCR-ABL1). Consistent with divergent pre-BCR activity in these
subsets, we found that TCF3-PBX1 but not BCR-ABL1 fusion
oncogenes induced expression of BCL6 in pre-B ALL cells (Fig-
ure 4E). Treatment with small molecule tyrosine kinase inhibitors
of SYK (PRT062607) and BTK (Ibrutinib) reduced BCL6 expres-
sion in pre-BCR+ TCF3-PBX1 ALL cells (Figures 4F and 4G),
demonstrating that SYK tyrosine kinase activity is required for
BCL6 expression in pre-BCR+ ALL cells. While TCF3-PBX1 in-
duces constitutive BCL6 expression via tonic pre-BCR signaling,
BCR-ABL1 represses BCL6 expression. Ph+ ALL lack BCL6
expression in the presence of active BCR-ABL1, however,
ABL1 tyrosine kinase inhibitors (Nilotinib, Dasatinib) relieve
BCR-ABL1/STAT5-mediated repression of BCL6 (Figure 4H).
Interestingly, the specific ABL1 kinase inhibitor Nilotinib, which
does not affect pre-BCR signaling, has no effect on constitutive
BCL6 expression in TCF3-PBX1 ALL cells. However, the dual
ABL1/SRC kinase inhibitor Dasatinib, which inhibits the SRC
kinases BLK, LYN, and FYN upstream of SYK, almost entirely
abolished BCL6 expression in pre-BCR+ TCF3-PBX1 ALL cells
(Figure 4H). These findings reveal that based on divergent func-
tions of pre-BCR/BCL6 signaling human ALL can be divided into
two genetically and phenotypically distinct subsets.
We propose that in themajority of ALL cases, the transforming
oncogene (e.g., BCR-ABL1) mimics constitutive active cytokine
signaling via activation of STAT5 and repression of BCL6. In
10%–15% of the cases, oncogenic lesions (e.g., TCF3-PBX1;
Table S8) result in tonic pre-BCR signaling and activation of
BCL6. These differences may reflect different cells of origins of
the two subsets. BCR-ABL1 engages IL7R-dependent survival
and proliferation signals via STAT5 that are active in pro-B and
early pre-B cells (Fraction C); in contrast, activation of pre-BCR
signaling (e.g., by TCF3-PBX1) in late pre-B cells (Fraction C’)
suppresses IL7R and cytokine signaling (Ochiai et al., 2012).
We propose that themutually exclusive nature of cytokine recep-
tor/STAT5 and pre-BCR/BCL6 pathways in human ALL reflects
distinct developmental origins from early (Fraction C) and late
(Fraction C’) pre-B cells (Figure 4I). BCL6 ChIPseq analysis
revealed that BCL6 and STAT5 binding sites were the most
highly enriched DNA elements (p = 1060 for both) associated
with BCL6 binding peaks in TCF3-PBX1 ALL cells (Figure 4I),
suggesting that BCL6 and STAT5 may compete for binding to
those promoters, which would be consistent with mutual exclu-
sive activity of STAT5 and BCL6 in pre-BCR and pre-BCR+ ALL
subtypes, respectively.
Genetic Mouse Model of Conditional BCL6 Ablation in
Pre-BCR+ TCF3-PBX1 ALL
BCL6 functions as a classical proto-oncogene in germinal cen-
ter-derived B cell lymphoma (Ye et al., 1993) and represents a
powerful survival factor at the pre-BCR checkpoint during earlye color scale indicates p values calculated from Ingenuity.
use bone marrow CD19+ ALL cells transduced with the MLL-ENL, BCR-ABL1,
tencies of 90–180 days in the bonemarrow from theMLL-AF4-,BCR-ABL1-, or
Cancer Cell 27, 409–425, March 9, 2015 ª2015 Elsevier Inc. 415
A B
D
C
F E
G
H
I
(legend on next page)
416 Cancer Cell 27, 409–425, March 9, 2015 ª2015 Elsevier Inc.
B cell development (Duy et al., 2010). For these reasons, we
developed a genetic mouse model to determine the role of
BCL6 in pre-BCR+ ALL cells. In Bcl6fl/fl-mCherry mice, exons
5–10 were flanked by LoxP sites and Cre-mediated deletion of
these exons results in expression of a truncated Bcl6 protein
fused to mCherry (Figure 5A). Thereby mCherry expression re-
flects transcriptional activity of the Bcl6 promoter and Cre-medi-
ated deletion can be used for inducible ablation of Bcl6 function
and as mCherry-based reporter of Bcl6 expression. In a genetic
experiment, we transduced Bcl6fl/fl-mCherry pre-B cells with
TCF3-PBX1 or an empty vector (EV) control. Cre-mediated dele-
tion (Figure 5B) activated the Bcl6-mCherry reporter (Figure 5C).
While only 1% of pre-B cells carrying an EV control showed
transcriptional activation of the Bcl6 promoter, more than 50%
of TCF3-PBX1-transduced cells actively transcribed Bcl6 (Fig-
ure 5C). These findings demonstrate that TCF3-PBX1 indirectly
induces Bcl6 expression through transcriptional activation of
pre-BCR signaling.
BCL6 Transcriptionally Activates Pre-BCR Components
in TCF3-PBX1 ALL
To identify BCL6 transcriptional targets in pre-BCR+ ALL cells,
we performed ChIPseq analysis in patient-derived TCF3-PBX1
ALL cells (Figures S4A–S4D). As in DLBCL and Ph+ ALL (Duy
et al., 2011), BCL6 directly binds to a number of checkpoint mol-
ecules, including RB1, CDKN2C, and CDKN1B in pre-BCR+ ALL
(Figure S4A). A previous study demonstrated that BCL6 in-
creases tonic BCR signaling in DLBCL cells by transcriptional
repression of the inhibitory phosphatase PTPRO (Juszczynski
et al., 2009). Likewise, PTPROwas also identified as a transcrip-
tional target of BCL6 in pre-BCR+ ALL cells. In addition, BCL6
also binds to pre-BCR components (IGLL1, VPREB1) and down-
stream signaling molecules (BLK, BANK1, SYK) (Figure 5D).
QChIP validated BCL6 binding to these loci (Figure S4B). To
determine how BCL6 binding affects gene expression in PBX1-
rearranged ALL cells, we measured gene expression changes
in response to acute ablation of Bcl6 in aBcl6fl/fl-mCherrymouse
model for TCF3-PBX1 ALL. Upon Cre-mediated deletion ofBcl6,
multiple BCL6 target genes were de-repressed, including
checkpoint molecules RB1, CDKN1A, CDKN1B, CDKN2A, andFigure 4. Pre-BCR Signaling in ALL Cells Drives Expression of BCL6
(A) BCL6, STAT5, and pSTAT5Y694 western blotting with b-actin as a loading
nonspecific band.
(B) Protein expression levels of BCL6, STAT5, and pSTAT5Y694 by western blot wi
Rag2/ tTA/m-chain ALL cells (left), before and after pre-BCR signaling reconsti
(middle), or CD8/m-chain or CD8 EV in Ighm/ ALL cells (right).
(C) BCL6 and STAT5 western blot in the presence or absence of Cre-mediated d
(D) Immunohistochemistry double-stainings for BCL6 (nuclear, brown) and mHC
marrow samples from pre-BCR and pre-BCR+ ALL patients. A Burkitt’s lymphom
positive control. Scale bars represent 20 mm.
(E) Bone marrow pre-B cells transduced with BCR-ABL1 or TCF3-PBX1 vecto
90–180 days from the BCR-ABL1- or TCF3-PBX1-transgenic mice were stained
expression threshold was set according to an isotype staining control.
(F andG) BCL6 protein expression bywestern blotting in presence or absence of S
in a TCF3-PBX1 ALL cell line (RCH-ACV) and a primary sample (ICN12).
(H) in presence or absence of Nilotinib (200 nmol/l) or Dasatinib (25 nmol/l) for 24
used as a loading control.
(I) A schematic of pre-BCR, STAT5 and BCL6 regulation in BCR-ABL1 and TCF3
See also Figure S3 and Tables S7 and S8.CDKN2C (Figures 5E and 5F). Also PTPRO were among the
de-repressed BCL6 target genes, suggesting that BCL6 in-
creases tonic pre-BCR signaling by transcriptional repression
of the (pre-)BCR signaling inhibitor PTPRO as described in
DLBCL (Juszczynski et al., 2009). Interestingly, BCL6 targets
with transcriptional activation by Bcl6 include multiple pre-BCR
related molecules (Bank1, Syk; Figures 5E and 5F). To test
BCL6-dependent gene regulation in ALL patient samples, we in-
tegrated BCL6 ChIPseq target genes with a BCL6-dependent
signature of gene expression in 118 cases of childhood pre-B
ALL (St. Jude). This analysis showed transcriptional activation
of 63 BCL6 target genes, including multiple pre-BCR related
molecules (IGLL1, BLK, VPREB1, PIK3CD, SYK; Figures 5G
and 5H). Collectively, these findings suggest a self-enforcing
activation loop between tonic pre-BCR signaling and BCL6
activity in a subset of human ALL: oncogenic activation of tonic
pre-BCR signaling (e.g., as a result of PBX1 rearrangement and
duplication) induces strong activation of BCL6, which further ac-
tivates pre-BCR signaling (e.g., through transcriptional repres-
sion of PTPRO and PRDM1 and activation of IGLL1, VPREB1,
BLK, SYK). Interestingly, PBX1 binding to promoter regions of
pre-BCR-related genes frequently co-localizes with binding of
BCL6, suggesting that BCL6 and PBX1 cooperate in the regula-
tion of these genes (Figure 5I).
Pre-BCR+ ALL Cells Are Dependent on BCL6 Activity
Pre-BCR+ ALL and BCR-dependent B cell lymphoma share
constitutively high BCL6 expression levels. To determine
whether high expression levels of BCL6 correlate with clinical
outcome of ALL patients, we analyzed mRNA levels of BCL6 at
the time of diagnosis in children with high-risk ALL (COG
P9906) and adults with ALL (ECOG E2993). Only patients of
known pre-BCR expression status were included in the analysis.
Since BCL6 was specifically upregulated by tonic pre-BCR
signaling, we performed clinical outcome analyses separately
for pre-BCR+ and pre-BCR ALL cases. In both the pediatric
(COG P9906, p = 0.043) and adult (ECOG E2993, p = 0.013) clin-
ical trials, higher than median expression levels of BCL6 were
predictive of poor outcome among patients with pre-BCR+ but
not pre-BCR ALL (Figures 6A and 6B). These findings suggestcontrol in human BCR-ABL1 or TCF3-PBX1 ALL samples. Asterisk denotes
th b-actin as the loading control at different time points of tetracycline culture of
tution by retroviral expression of Blnk-GFP or GFP EV in the Blnk/ ALL cells
eletion of Stat5 in Stat5fl/fl pre-B ALL cells.
(cytoplasmic/membrane, red) on the same slides of paraffin-embedded bone
a sample (12–926) carrying an IGH-BCL6 gene rearrangement was used as a
rs or from full-blown ALL populations that had developed after latencies of
for intracellular Bcl6 protein. Cells were gated as live CD19+ cells. The Bcl6
YK inhibitor (PRT062607, 10 mmol/l), BTK inhibitor (Ibrutinib, 10 mmol/l) for 24 hr
hr in primary BCR-ABL1 (ICN1) or TCF3-PBX1 (ICN12) ALL cells. b-actin was
-PBX1 ALL.
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that high expression levels of BCL6 affect the course of disease
in pre-BCR+ but not pre-BCR ALL. To determine the potential
contribution of BCL6 signaling to survival and proliferation of
pre-BCR+ ALL cells, we studied inducible ablation of Bcl6 in
a mouse model (Figures 5A–5C). Bcl6fl/fl TCF3-PBX1 ALL cells
were transduced with 4-hydroxy-tamoxifen (4-OHT)-inducible
Cre (Cre-ERT2) or an EV control (ERT2). While 4-OHT mediated
deletion of Bcl6 resulted in progressive depletion of Cre-ERT2-
transduced cells, it had no measurable effects in ERT2-
transduced Bcl6fl/fl TCF3-PBX1 ALL cells (Figure 6C). To verify
BCL6 dependency of pre-BCR+ ALL in a patient-derived setting,
we transduced xenografted TCF3-PBX1 ALL cells with an induc-
ible dominant-negative BCL6 mutant lacking the BCL6-BTB
domain (DNBCL6-ERT2) (Shaffer et al., 2000). While the fraction
of ICN12 cells carrying ERT2 EVs remained stable after 4-OHT
treatment, cells transduced with DNBCL6-ERT2 were rapidly
depleted (Figure 6D). These findings collectively identify BCL6
as a potential target for the treatment of pre-BCR+ ALL.
Pharmacological Inhibition of BCL6 in Pre-BCR+
ALL Cells
In a complementary approach, we tested the consequences
of shRNA-mediated knockdown of BCL6 in pre-BCR+ ALL
cells. Upon doxycycline-inducible expression of BCL6-specific
shRNAs, we observed moderate reduction of BCL6 protein
expression and impaired colony formation capacity in pre-
BCR+ ALL cells (Figures S5A–S5C). For proof-of-principle exper-
iments, a specific retro-inverso BCL6 peptide-inhibitor (RI-BPI)
was used to inhibit BCL6 function (Cerchietti et al., 2009). Treat-
ment of patient-derived pre-BCR+ ALL cells with 5 mmol/l RI-BPI
induced cell cycle arrest within 1 day of treatment (Figures 6E
and S5D) and caused impaired colony formation capacity (Fig-
ure S5E). Whereas RI-BPI treatment alone did not induce signif-
icant acute toxicity, it strongly sensitized pre-BCR+ ALL cells to
Vincristine (1 nmol/l, p = 0.003; Figures 6F and S5F), a mitotic
spindle inhibitor that is part of the chemotherapy backbone in
most current clinical trials for ALL. In conclusion, BCL6 repre-
sents a predictor of poor clinical outcome and a potential target
for therapy of patients with pre-BCR+ ALL.
Pre-BCR+ and Pre-BCR– ALL Cells Exhibit Distinct
Kinase-Inhibitor Sensitivity Profiles
Besides inhibition of BCL6 expression (Figures 4F–4H and S6A),
PRT062607 (SYK), Ibrutinib (BTK), and Dasatinib (SRC) inducedFigure 5. BCL6 Is a Key Regulator of the Transcriptional Program in P
(A) A geneticmodel for inducible ablation ofBCL6 and amCherry-based Bcl6 repo
Cre-mediated deletion. LoxP sites are indicated as black triangles.
(B) PCR validation of the floxed, deleted, and WT Bcl6 allele from Bcl6fl/fl-mCher
(C) FACS analysis of EVNeo or TCF3-PBX1Neo retrovirally transducedBcl6fl/fl-mChe
deletion. y axis indicates mCherry expression, and x axis indicates GFP express
(D) BCL6 ChIPseq binding tracks of target genes in patient-derived TCF3-PBX
normalized by the total number of reads per track. Gene models are shown in UC
negative and positive controls.
(E and F) A meta-analysis of BCL6 ChIPseq target genes (n = 666) with gene exp
ALL cells.
(G and H) for the BCL6High versus BCL6Low ALL patient samples from St. Jude.
target genes in each dataset. The color scale bar represents relative log2 expres
(I) PBX1 and BCL6 ChIPseq binding tracks versus input in ICN12 cells on pre-BC
See also Figure S4.selective toxicity in pre-BCR+ ALL cells (Figure 7A). Pre-BCR+
ALL (n = 7), pre-BCR ALL (n = 8), and mature B cell lymphoma
cells (n = 2) were treated with inhibitors of pre-BCR tyrosine
kinases PRT062607 (SYK), Ibrutinib (BTK), Dasatinib (SRC), as
well as inhibitors of pre-BCR downstream signaling, including
GS-1101 (PI3Kd), AZD05363 (AKT1), Rapamycin (mTOR),
AZD6244 (MEK1), SCH772984 (ERK1, ERK2), Enzastaurin
(PKCb), MI2 (MALT1), and BMS345541 (IKK, NF-kB) (Fig-
ure S6B). For treatment with the dual SRC/ABL1 kinase inhibitor
Dasatinib, only Ph+ ALL cells expressing mutant BCR-ABL1T315I
were studied to rule out effects of BCR-ABL1 tyrosine kinase
inhibition. Compared with pre-BCR ALL and mature B cell lym-
phoma cells, pre-BCR+ ALL cells were selectively sensitive to
inhibition of SYK and SRC (BLK, LYN) and, to some lesser de-
gree, to inhibition of BTK (Figure 7A) and PI3Kd (Figure S6B).
On the other hand, pre-BCR ALL cells were selectively sensi-
tive to inhibitors of MEK1 (AZD6244) and ERK1/2 (SCH772984),
suggesting that pre-BCR+ and pre-BCR ALL cells can be
distinguished based on a specific profile of kinase-inhibitor
sensitivity.
To address this possibility in a formal experiment, we treated
pre-BCR+ (n = 8) and pre-BCR (n = 9) ALL cells with a diverse
panel of 51 kinase inhibitors that are currently being studied for
the treatment of hematological malignancies and solid tumors
(Figure 7B). This analysis confirmed that pre-BCR+ ALL cells
are particularly sensitive to inhibitors of SYK, SRC, and PIK3d,
whereas pre-BCR ALL cells are more responsive to inhibition
of MEK1 and ERK1/2 (Figure 7B). Integrating experimentally
measured sensitivities to individual inhibitors with their known
biochemical IC50 values for individual kinase targets, we estab-
lished a kinase dendrogram of specific vulnerabilities of pre-
BCR+ and pre-BCR ALL (Figure 7C). While pre-BCR+ ALL cells
were most dependent on SYK, ZAP70, BTK, and LYN activity,
pre-BCR ALL cells were most vulnerable to inhibition of
ABL1, PDGFR, ERK1, ERK2, MET, and KIT kinase activity
(Figure 7C).
Validation of Pre-BCR-BCL6 Signaling as a Therapeutic
Target in Pre-BCR+ ALL Cells
The usefulness of pre-BCR signaling inhibitors PRT062607
(SYK), Ibrutinib (BTK), and Dasatinib (SRC, BTK) for the treat-
ment of pre-BCR+ ALL was tested in a proof-of-principle exper-
iment. To this end, one million patient-derived TCF3-PBX1 pre-
BCR+ ALL cells (ICN12) labeled with luciferase were injectedre-BCR+ ALL Cells
rter (Bcl6fl/fl-mCherry). Exons 5–10 of theBcl6 locus were targeted for inducible
ry mouse bone marrow pre-B cells.
rry pre-B cells that were transducedwith either EVGFP or CreGFP vector forBcl6
ion.
1 ALL cells (ICN12). y axis represents the number of reads for peak summit
SC genome browser hg18. A control intragenic region and BCL6 were used as
ression microarray data for the EV versus Cre transduced Bcl6fl/fl TCF3-PBX1
The scatter or heat-map plots showed upregulated and downregulated BCL6
sion changes.
R-related genes (IGLL1, VPREB1, BLK, BANK1).
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intravenously into sublethally irradiated NOD/SCID mice.
Recipient mice were then treated with vehicle (n = 11),
PRT062607 (100 mg/kg, n = 7), Ibrutinib (75 mg/kg, n = 7),
and Dasatinib (40 mg/kg, n = 12). All of the inhibitors were
well tolerated and achieved significant reduction of leukemia
burden in vivo, as determined by luciferase bioimaging (Fig-
ure 8A). These experiments, together with in vitro testing (Fig-
ures 7A and 7B), suggested that Dasatinib has the strongest
anti-leukemic effect among the three pre-BCR signaling inhibi-
tors. For this reason, we prioritized Dasatinib for detailed in vitro
validation experiments for a group of 135 patient-derived ALL
samples, including various ALL subtypes but not Ph+ ALL. Pa-
tient-derived ALL cells were cultured over 72 hr in the absence
or presence of Dasatinib in concentrations ranging from 1 to
1,000 nmol/l to calculate Dasatinib IC50 values for these cases.
Our previous kinase inhibitor screening assays (Tyner et al.,
2013) showed that the median IC50 for Dasatinib of all hemato-
logic malignancy samples received at OHSU (n > 400) was
900 nmol/l. Importantly, all 22 pre-BCR+ ALL cases were sensi-
tive to Dasatinib (IC50 < 50 nmol/l). In contrast, only 6 of 113
pre-BCR ALL cases had IC50 < 50 nmol/l, and the vast major-
ity of these cases did not respond to Dasatinib at concentra-
tions up to 1,000 nmol/l (Figure 8B). Based on a large dataset
from 135 patient-derived ALL samples, we conclude that Dasa-
tinib has strong selective antileukemia effects on pre-BCR+ ALL
cases. To confirm efficacy of Dasatinib in vivo, we transplanted
leukemia cells from four patients with pre-BCR+ ALL into suble-
thally irradiated NOD/SCID mice. Three of these cases carried a
TCF3-PBX1 gene rearrangement, and one case is hypodiploid.
In one case (07-112), treatment with Dasatinib alone was suffi-
cient to eradicate ALL and to cure mouse transplant recipients,
whereas vehicle-treated mice died within 130 days after injec-
tion (Figure 8C). In the three other cases, Dasatinib treatment
significantly delayed leukemic expansion and prolonged overall
survival of transplant recipient mice. A composite Kaplan-Meier
analysis of the four cases injected into a total of 25 mice per
group showed a substantial benefit of Dasatinib treatment
(p = 0.0001; Figure 8C). To monitor expansion of human leuke-
mia cells (expressing human CD19 and CD45) in the recipient
mice, peripheral blood from these mice was drawn weekly
and analyzed for chimerism. The Dasatinib-treated cohorts
showed minimal signs of circulating human chimerism
comparing to the untreated cohorts (Figure 8C). These results
demonstrate feasibility and efficacy of leukemia clearance
in vivo of pre-BCR+ ALL by Dasatinib based on four patient-
derived samples. We expect that combinations with other
pre-BCR signaling inhibitors (e.g., PRT062607, Ibrutinib) mayFigure 6. Pre-BCR+ ALL Cells Are Dependent on BCL6 Activity
(A and B) Patients were segregated into two groups based on higher or lower than
trials: (A) COG P9906 and (B) ECOG E2993. Kaplan-Myer estimates were used to
(C) Bcl6fl/fl TCF3-PBX1 pre-B ALL cells were transduced with 4-OHT-inducible C
was measure by flow cytometry at different time points following 4-OHT treatme
(D) Patient-derived Pre-BCR+ ALL cells (ICN12) were transduced with 4-OHT-indu
Percentages of GFP-positive cells were measured by the flow cytometry at diffe
(E) ICN12 cells were treated with vehicle or 5 mmol/l RI-BPI for 24 hr and then su
(F) ICN12 cells were exposed to vehicle, Vincristine (1 nmol/l), RI-BPI (5 mmol/l), or c
flow cytometry for Annexin V and 7-AAD staining. Data represent means ± SEM
See also Figure S5.have synergistic effects, which will be the focus of future
studies by our group.
DISCUSSION
Recent analyses revealed that BCR-dependent B cell lym-
phomas can be divided based on tonic or chronic active BCR
signaling (Davis et al., 2010; Rickert, 2013; Schmitz et al.,
2012). Tonic BCR signaling involves activation of one single
pathway, namely PI3Kd signaling downstream of SRC (LYN,
FYN, BLK) and SYK (Burger and Okkenhaug, 2014; Chen
et al., 2013) and is associated with germinal center B cell-like
(GCB-) DLBCL and Burkitt’s lymphoma (Young and Staudt,
2013). On the other hand, chronic active BCR signaling in
ABC-DLBCL, CLL andMCL engagesmultiple downstream path-
ways including BTK (and its downstream targets PKCb, MALT1,
and NF-kB), calcineurin/NFAT, andMEK/Erk (Young and Staudt,
2013). While the majority of B cell lymphoma cases are BCR
dependent and sensitive to BCR signaling antagonists, classical
Hodgkin’s lymphoma (Kanzler et al., 1996), and primary medias-
tinal B cell lymphoma (PMBL) (Leitha¨user et al., 2001) together
account for 15%–20% of human B cell lymphoma and lack
BCR function. The classification of B cell lymphoma based on
(1) chronic active, (2) tonic, and (3) lack of BCR signaling
informed the development of new treatment strategies and has
led to the successful introduction of BTK (chronic active) (Byrd
et al., 2013a, 2013b; Wang et al., 2011) and PI3Kd (tonic BCR
signaling) inhibitors (Gopal et al., 2014) into patient care.
Like mature B cell lymphoma, pre-B ALL originates from B cell
precursors that critically depend on survival signals emanating
from a functional (pre-)BCR. In contrast to B cell lymphoma,
however, a classification of human ALL based on pre-BCR func-
tion and activity is not available. Studying 830 ALL cases from
four clinical trials, we found no functional equivalent of chronic
active BCR signaling in B cell lymphoma. In the majority of ALL
cases, ALL cells lacked pre-BCR signaling (pre-BCR), a func-
tional equivalent to classical Hodgkin’s lymphoma and PBML
among mature B cell malignancies. However, in about 13.5%
of human ALL cases, ALL cells expressed a functional pre-
BCR (pre-BCR+) and were highly sensitive to inhibition of SYK
and SRC kinases and relatively resistant to inhibition of PKCb,
MALT1, and IKK/NF-kB.
Unlike ABC-DLBCL (chronic active BCR signaling), GCB-
DLBCL express high levels of BCL6 in the context of tonic
BCR signaling (Juszczynski et al., 2009). Here we found
constitutive and pre-BCR-dependent expression of BCL6 in
all pre-BCR+ ALL cases studied. Conversely, as a marker inthe median expression of BCL6 in pre-BCR+ and pre-BCR- ALL in two clinical
plot the survival probabilities; p values were calculated from the log-rank test.
re (Cre-ERT2-GFP) or EV control (ERT2-GFP). Percentage of GFP-positive cells
nt, and time course data are depicted.
cible dominant-negative BCL6 (DNBCL6-ERT2-GFP) or EV control (ERT2-GFP).
rent time points following 4-OHT treatment.
bjected to cell-cycle analysis (BrdU and 7-AAD staining).
ombination of Vincristine (1 nmol/l) and RI-BPI (5 mmol/l) for 3 days, followed by
(n = 3); p values from t test.
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Figure 7. Validation of Pharmacological Inhibition of BCL6-Pre-BCR Signaling as Therapeutic Target in Pre-BCR+ ALL Cells
(A) Cell viability wasmeasured using CCK-8 in presence or absence of PRT062607 (SYK), Ibrutinib (BTK), or Dasatinib (ABL1/SRC/BTK) for 72 hr with gradients of
concentrations as indicated in the x axis in pre-BCR+ ALL (n = 7), pre-BCR ALL (n = 8) and 2 Burkitt lymphoma (MN60, MHH-preB). y axis shows the percentage
of viable cells with the untreated cells as control (set to 100%). Data represent means ± SD (n = 3).
(B) Pre-BCR+ (n = 8) and pre-BCR (n = 9) patient-derived ALL samples were treated with a diverse panel of 51 kinase inhibitors as described previously (Tyner
et al., 2013). The heat map represents the IC50 values for each sample relative to the observed median IC50 value for over 400 primary leukemia samples
interrogated by this assay at OHSU. Red or blue colors denote higher or lower than the median sensitivity of the pre-B ALL cells tested. Pre-BCR+ ALL: 07-112,
11-064, ICN12, 697, RCH-ACV, Kasumi-2, HPB null, Nalm6. Pre-BCR ALL: BV173, SUPB15, BLQ5, LAX2, SEM, RS4;11, REH, LAX7R, SFO3.
(C) Kinase dendrogram of pre-BCR+ and pre-BCR ALL based on experimentally measured sensitivities to individual inhibitors and their known inhibitory profile
based on biochemical IC50 values for individual kinase targets. TREESpots software was used (KINOMEscan, http://www.discoverx.com/home).
See also Figure S6.immunohistochemistry staining, BCL6 reliably identified pre-
BCR+ ALL cases. BCL6 expression is indeed dependent on tonic
pre-BCR signaling, as small molecule inhibition of SYK and SRC
family kinases abolished BCL6 expression in pre-BCR+ ALL
cells. Since functional assays to measure tonic pre-BCR
signaling in ALL patient samples may not be practical for diag-
nostic purposes, we propose that BCL6 and mHC immunostain-
ing may be a feasible alternative to rapidly identify patients that422 Cancer Cell 27, 409–425, March 9, 2015 ª2015 Elsevier Inc.might benefit from treatment with inhibitors of tonic pre-BCR
signaling (e.g., SYK, SRC, PIK3d).EXPERIMENTAL PROCEDURES
Primary Human Samples and Cell Lines
After informed consent from all participants, primary ALL cases were obtained
with the approval of the Institutional Review Boards of the University of
A C
B
Figure 8. Validation of Pharmacological Inhibition of BCL6-Pre-BCR Signaling in Patient-Derived Pre-BCR+ ALL Cells
(A) Patient-derived pre-BCR+ ALL cells (ICN12) were labeled with luciferase and 1-million cells were injected intravenously to sublethally irradiated NOD/SCID
mice. The mice were randomly separated into four groups and treated with vehicle, the SYK inhibitor PRT062607 (100 mg/kg), the BTK inhibitor Ibrutinib
(75 mg/kg), or Dasatinib (40 mg/kg) respectively. Bioimages were taken at different time points for each of the groups.
(B) Plot of Dasatinib IC50s from primary ALL patient samples (n = 135, OHSU). ALL samples were cultured over 72 hr in the presence or absence of Dasatinib in
concentrations ranging from 1 to 1,000 nmol/l to calculate the IC50 values.
(C) Patient-derived pre-BCR+ ALL cells (n = 4) were injected to sublethally irradiated NOD/SCID mice. Mice were treated with vehicle or Dasatinib (40–50 mg/kg).
Kaplan-Meier estimates were used to plot the survival probabilities for each treatment group versus vehicle control; p values were calculated from log-rank test.
Peripheral blood was drawn weekly and analyzed for chimerism with either human CD19 or human CD45 versus murine CD45 and plotted over time. Data
represent means ± SD (n = 4 or 5).California San Francisco (UCSF) and Oregon Health and Science University
(OHSU). Primary human ALL samples were cultured on OP9 stroma in mini-
mum essential medium (MEMa; Life Technologies) with GlutaMAX containing
20% fetal bovine serum (FBS), 100-IU ml1 penicillin, 100-mg ml1 strepto-
mycin, and 1-mM sodium pyruvate at 37C in a humidified incubator with
5%CO2. The human cell lines were purchased fromDSMZ. See Tables S1–S3.
In Vivo Leukemia Cell Transplantation and Treatment
All mouse experiments were subject to institutional approval by the
University of California San Francisco Institutional Animal Care and Use
Committee; 106 cells from primary TCF3-PBX1 pre-BCR+ ALL were inocu-lated via intravenous injection into sublethally irradiated (250 cGy) adult
female NOD/SCID mice (n = 37). After injection of leukemia cells, the
mice were randomly separated into four groups and treated with (1)
Dasatinib (40 mg/kg, n = 12), (2) Ibrutinib (75 mg/kg, n = 7), (3)
PRT062607 (100 mg/kg, n = 7), and (4) vehicle (n = 11). Leukemic infiltration
was confirmed by flow cytometry and bioimaging.
Statistical Analysis
The Kaplan-Meier method was used to estimate overall survival. Log-rank
test was used to compare survival differences between patient groups. The
R package ‘‘survival’’ v.2.35-8 was used for the survival analysis.Cancer Cell 27, 409–425, March 9, 2015 ª2015 Elsevier Inc. 423
ACCESSION NUMBERS
The gene expression microarray and ChIPseq data reported in this paper
have been deposited in the NCBI Gene Expression Omnibus (GEO) (http://
www.ncbi.nlm.nih.gov/geo) database with the GEO accession numbers
GSE59332 and GSE59538.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2015.02.003.
AUTHOR CONTRIBUTIONS
H.G., C.H., and K.B.L. designed and performed themajority of the analysis and
experiments. Z.C., D.B., S.T., N.A.G., W.-Y.C., J.H., D.L, E.B., G.X., J.-W.L.,
A.D., Z.Q., E.P., C.H., R.N., S.-M.K., S.S., L.N.C., J.Y., J.W.T., B.H.C.,
S.M.K., and T.A.M. performed experiments and analyzed data. H.G., A.D.,
S.M.K., E.P., A.M., S.P.H., M.L.L., and B.H.C. provided and characterized pa-
tient samples and clinical outcome data. J.J.B., B.H.Y., K.M.A., A.M., J.A.B.,
R.G.R., and M.M. provided important reagents and mouse samples. M.M.
and B.H. designed experiments and conceived the study. M.M. wrote the
paper.
ACKNOWLEDGMENTS
We thank Michael L. Cleary (Stanford) for critical discussions, Arthur L. Shaffer
and Louis M Staudt for inducible BCL6 constructs, Mark Kamps and David B.
Sykes for inducible TCF3-PBX1 vectors, Lothar Hennighausen for Stat5abfl/fl
mice, and Julia Gastier-Foster and I-Ming Chen for fresh samples from the
COG ALL Biology Bank (proposal number 2008-08). This work is supported
by grants from the NIH/NCI through R01CA137060, R01CA139032,
R01CA157644, R01CA169458, R01CA172558 (to M.M.), CA178765 and
CA163068 (to R.G.R.), R00CA151457 and R01CA183947 (to J.W.T.), U10
CA98543 (COG Chair’s grant), U10 CA98413 (COG Statistical Center), and
U24 CA114766 (COG Specimen Banking), the Hyundai Hope on Wheels, the
St. Baldrick’s Foundation, the Leukemia & Lymphoma Society Specialized
Center of Research (LLS SCOR) and Tucker’s Toy Box Foundation (to
B.H.C.), the William Lawrence and Blanche Hughes Foundation, the California
Institute for Regenerative Medicine (CIRM; TR2-01816), Leukaemia and Lym-
phoma Research (to M.M.), the Medical Research Council and the National
Institute for Health Research Oxford Biomedical Research Centre Program
(to T.M. and E.B.). B.J.D. is supported by the Howard Hughes Medical Insti-
tute. M.M. is a Scholar of the Leukemia and Lymphoma Society and a Senior
Investigator of the Wellcome Trust.
Received: September 2, 2014
Revised: December 22, 2014
Accepted: February 10, 2015
Published: March 9, 2015
REFERENCES
Bayly, R., Chuen, L., Currie, R.A., Hyndman, B.D., Casselman, R., Blobel, G.A.,
and LeBrun, D.P. (2004). E2A-PBX1 interacts directly with the KIX domain of
CBP/p300 in the induction of proliferation in primary hematopoietic cells.
J. Biol. Chem. 279, 55362–55371.
Bicocca, V.T., Chang, B.H., Masouleh, B.K., Muschen, M., Loriaux, M.M.,
Druker, B.J., and Tyner, J.W. (2012). Crosstalk between ROR1 and the pre-
B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.
Cancer Cell 22, 656–667.
Burger, J.A., and Okkenhaug, K. (2014). Haematological cancer: idelalisib—
targeting PI3Kd in patients with B-cell malignancies. Nat. Rev. Clin. Oncol.
11, 184–186.
Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A.,
Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., et al. (2013a).424 Cancer Cell 27, 409–425, March 9, 2015 ª2015 Elsevier Inc.Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
N. Engl. J. Med. 369, 32–42.
Byrd, J.C., O’Brien, S., and James, D.F. (2013b). Ibrutinib in relapsed chronic
lymphocytic leukemia. N. Engl. J. Med. 369, 1278–1279.
Cerchietti, L.C., Yang, S.N., Shaknovich, R., Hatzi, K., Polo, J.M., Chadburn,
A., Dowdy, S.F., and Melnick, A. (2009). A peptomimetic inhibitor of BCL6
with potent antilymphoma effects in vitro and in vivo. Blood 113, 3397–3405.
Chen, L., Juszczynski, P., Takeyama, K., Aguiar, R.C., and Shipp, M.A. (2006).
Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates
SYK phosphorylation, proximal B-cell-receptor signaling, and cellular prolifer-
ation. Blood 108, 3428–3433.
Chen, L., Monti, S., Juszczynski, P., Ouyang, J., Chapuy, B., Neuberg, D.,
Doench, J.G., Bogusz, A.M., Habermann, T.M., Dogan, A., et al. (2013). SYK
inhibition modulates distinct PI3K/AKT- dependent survival pathways and
cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 23,
826–838.
Cheng, S., Coffey, G., Zhang, X.H., Shaknovich, R., Song, Z., Lu, P., Pandey,
A., Melnick, A.M., Sinha, U., and Wang, Y.L. (2011). SYK inhibition and
response prediction in diffuse large B-cell lymphoma. Blood 118, 6342–6352.
Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B.,
Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010). Chronic active
B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88–92.
Duy, C., Yu, J.J., Nahar, R., Swaminathan, S., Kweon, S.M., Polo, J.M., Valls,
E., Klemm, L., Shojaee, S., Cerchietti, L., et al. (2010). BCL6 is critical for the
development of a diverse primary B cell repertoire. J. Exp. Med. 207, 1209–
1221.
Duy, C., Hurtz, C., Shojaee, S., Cerchietti, L., Geng, H., Swaminathan, S.,
Klemm, L., Kweon, S.M., Nahar, R., Braig, M., et al. (2011). BCL6 enables
Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibi-
tion. Nature 473, 384–388.
Geng, H., Brennan, S., Milne, T.A., Chen, W.Y., Li, Y., Hurtz, C., Kweon, S.M.,
Zickl, L., Shojaee, S., Neuberg, D., et al. (2012). Integrative epigenomic anal-
ysis identifies biomarkers and therapeutic targets in adult B-acute lympho-
blastic leukemia. Cancer Discov. 2, 1004–1023.
Gopal, A.K., Kahl, B.S., de Vos, S., Wagner-Johnston, N.D., Schuster, S.J.,
Jurczak, W.J., Flinn, I.W., Flowers, C.R., Martin, P., Viardot, A., et al. (2014).
PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma.
N. Engl. J. Med. 370, 1008–1018.
Guo, B., Kato, R.M., Garcia-Lloret, M., Wahl, M.I., and Rawlings, D.J. (2000).
Engagement of the human pre-B cell receptor generates a lipid raft-dependent
calcium signaling complex. Immunity 13, 243–253.
Harvey, R.C., Mullighan, C.G., Wang, X., Dobbin, K.K., Davidson, G.S.,
Bedrick, E.J., Chen, I.M., Atlas, S.R., Kang, H., Ar, K., et al. (2010).
Identification of novel cluster groups in pediatric high-risk B-precursor
acute lymphoblastic leukemia with gene expression profiling: correlation
with genome-wide DNA copy number alterations, clinical characteristics,
and outcome. Blood 116, 4874–4884.
Juszczynski, P., Chen, L., O’Donnell, E., Polo, J.M., Ranuncolo, S.M., Dalla-
Favera, R., Melnick, A., and Shipp, M.A. (2009). BCL6 modulates tonic BCR
signaling in diffuse large B-cell lymphomas by repressing the SYK phospha-
tase, PTPROt. Blood 114, 5315–5321.
Kanzler, H., Ku¨ppers, R., Hansmann, M.L., and Rajewsky, K. (1996). Hodgkin
and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth
of a dominant tumor clone derived from (crippled) germinal center B cells.
J. Exp. Med. 184, 1495–1505.
Ke, J., Chelvarajan, R.L., Sindhava, V., Robertson, D.A., Lekakis, L., Jennings,
C.D., and Bondada, S. (2009). Anomalous constitutive Src kinase activity
promotes B lymphoma survival and growth. Mol. Cancer 8, 132.
Kraus, M., Alimzhanov, M.B., Rajewsky, N., and Rajewsky, K. (2004). Survival
of resting mature B lymphocytes depends on BCR signaling via the Igalpha/
beta heterodimer. Cell 117, 787–800.
Leitha¨user, F., Ba¨uerle, M., Huynh, M.Q., and Mo¨ller, P. (2001). Isotype-
switched immunoglobulin genes with a high load of somatic hypermutation
and lack of ongoing mutational activity are prevalent in mediastinal B-cell
lymphoma. Blood 98, 2762–2770.
Nourse, J., Mellentin, J.D., Galili, N., Wilkinson, J., Stanbridge, E., Smith, S.D.,
andCleary, M.L. (1990). Chromosomal translocation t(1;19) results in synthesis
of a homeobox fusion mRNA that codes for a potential chimeric transcription
factor. Cell 60, 535–545.
Ochiai, K., Maienschein-Cline, M., Mandal, M., Triggs, J.R., Bertolino, E.,
Sciammas, R., Dinner, A.R., Clark, M.R., and Singh, H. (2012). A self-reinforc-
ing regulatory network triggered by limiting IL-7 activates pre-BCR signaling
and differentiation. Nat. Immunol. 13, 300–307.
Okada, T., Maeda, A., Iwamatsu, A., Gotoh, K., and Kurosaki, T. (2000). BCAP:
the tyrosine kinase substrate that connects B cell receptor to phosphoinositide
3-kinase activation. Immunity 13, 817–827.
Osmond, D.G. (1991). Proliferation kinetics and the lifespan of B cells in central
and peripheral lymphoid organs. Curr. Opin. Immunol. 3, 179–185.
Rajewsky, K. (1996). Clonal selection and learning in the antibody system.
Nature 381, 751–758.
Ramadani, F., Bolland, D.J., Garcon, F., Emery, J.L., Vanhaesebroeck, B.,
Corcoran, A.E., and Okkenhaug, K. (2010). The PI3K isoforms p110alpha
and p110delta are essential for pre-B cell receptor signaling and B cell devel-
opment. Sci. Signal. 3, ra60.
Rickert, R.C. (2013). New insights into pre-BCR and BCR signalling with rele-
vance to B cell malignancies. Nat. Rev. Immunol. 13, 578–591.
Ross, M.E., Zhou, X., Song, G., Shurtleff, S.A., Girtman, K., Williams, W.K., Liu,
H.C., Mahfouz, R., Raimondi, S.C., Lenny, N., et al. (2003). Classification of
pediatric acute lymphoblastic leukemia by gene expression profiling. Blood
102, 2951–2959.
Saijo, K., Schmedt, C., Su, I.H., Karasuyama, H., Lowell, C.A., Reth, M.,
Adachi, T., Patke, A., Santana, A., and Tarakhovsky, A. (2003). Essential role
of Src-family protein tyrosine kinases in NF-kappaB activation during B cell
development. Nat. Immunol. 4, 274–279.
Sakaguchi, N., and Melchers, F. (1986). Lambda 5, a new light-chain-related
locus selectively expressed in pre-B lymphocytes. Nature 324, 579–582.
Sanyal, M., Tung, J.W., Karsunky, H., Zeng, H., Selleri, L., Weissman, I.L.,
Herzenberg, L.A., and Cleary, M.L. (2007). B-cell development fails in the
absence of the Pbx1 proto-oncogene. Blood 109, 4191–4199.
Schmitz, R., Young, R.M., Ceribelli, M., Jhavar, S., Xiao,W., Zhang, M.,Wright,
G., Shaffer, A.L., Hodson, D.J., Buras, E., et al. (2012). Burkitt lymphoma path-
ogenesis and therapeutic targets from structural and functional genomics.
Nature 490, 116–120.Schweighoffer, E., Vanes, L., Mathiot, A., Nakamura, T., and Tybulewicz, V.L.
(2003). Unexpected requirement for ZAP-70 in pre-B cell development and
allelic exclusion. Immunity 18, 523–533.
Shaffer, A.L., Yu, X., He, Y., Boldrick, J., Chan, E.P., and Staudt, L.M. (2000).
BCL-6 represses genes that function in lymphocyte differentiation, inflamma-
tion, and cell cycle control. Immunity 13, 199–212.
Srinivasan, L., Sasaki, Y., Calado, D.P., Zhang, B., Paik, J.H., DePinho, R.A.,
Kutok, J.L., Kearney, J.F., Otipoby, K.L., and Rajewsky, K. (2009). PI3 kinase
signals BCR-dependent mature B cell survival. Cell 139, 573–586.
Swaminathan, S., Huang, C., Geng, H., Chen, Z., Harvey, R., Kang, H., Ng, C.,
Titz, B., Hurtz, C., Sadiyah, M.F., et al. (2013). BACH2 mediates negative
selection and p53-dependent tumor suppression at the pre-B cell receptor
checkpoint. Nat. Med. 19, 1014–1022.
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G.B., and Kornblau,
S.M. (2006). Reverse phase protein array: validation of a novel proteomic tech-
nology and utility for analysis of primary leukemia specimens and hematopoi-
etic stem cells. Mol. Cancer Ther. 5, 2512–2521.
Trageser, D., Iacobucci, I., Nahar, R., Duy, C., von Levetzow, G., Klemm, L.,
Park, E., Schuh, W., Gruber, T., Herzog, S., et al. (2009). Pre-B cell receptor-
mediated cell cycle arrest in Philadelphia chromosome-positive acute lympho-
blastic leukemia requires IKAROS function. J. Exp. Med. 206, 1739–1753.
Tyner, J.W., Yang, W.F., Bankhead, A., 3rd, Fan, G., Fletcher, L.B., Bryant, J.,
Glover, J.M., Chang, B.H., Spurgeon, S.E., Fleming, W.H., et al. (2013). Kinase
pathway dependence in primary human leukemias determined by rapid inhib-
itor screening. Cancer Res. 73, 285–296.
Wang, L., Li, L., Zhang, H., Luo, X., Dai, J., Zhou, S., Gu, J., Zhu, J., Atadja, P.,
Lu, C., et al. (2011). Structure of human SMYD2 protein reveals the basis of
p53 tumor suppressor methylation. J. Biol. Chem. 286, 38725–38737.
Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., Jurczak, W.,
Advani, R.H., Romaguera, J.E., Williams, M.E., et al. (2013). Targeting BTK
with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J.
Med. 369, 507–516.
Yang, C., Lu, P., Lee, F.Y., Chadburn, A., Barrientos, J.C., Leonard, J.P., Ye,
F., Zhang, D., Knowles, D.M., andWang, Y.L. (2008). Tyrosine kinase inhibition
in diffuse large B-cell lymphoma: molecular basis for antitumor activity and
drug resistance of dasatinib. Leukemia 22, 1755–1766.
Ye, B.H., Lista, F., Lo Coco, F., Knowles, D.M., Offit, K., Chaganti, R.S., and
Dalla-Favera, R. (1993). Alterations of a zinc finger-encoding gene, BCL-6, in
diffuse large-cell lymphoma. Science 262, 747–750.
Young, R.M., and Staudt, L.M. (2013). Targeting pathological B cell receptor
signalling in lymphoid malignancies. Nat. Rev. Drug Discov. 12, 229–243.Cancer Cell 27, 409–425, March 9, 2015 ª2015 Elsevier Inc. 425
